267 related articles for article (PubMed ID: 29562801)
1. Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy.
Zielen S; Gabrielpillai J; Herrmann E; Schulze J; Schubert R; Rosewich M
Immunotherapy; 2018 Jun; 10(7):529-536. PubMed ID: 29562801
[TBL] [Abstract][Full Text] [Related]
2. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study.
Pfaar O; Barth C; Jaschke C; Hörmann K; Klimek L
Int Arch Allergy Immunol; 2011; 154(4):336-44. PubMed ID: 20975285
[TBL] [Abstract][Full Text] [Related]
3. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro).
McCormack PL; Wagstaff AJ
Drugs; 2006; 66(7):931-8. PubMed ID: 16740007
[TBL] [Abstract][Full Text] [Related]
4. Ultra-short-course booster allergen immunotherapy.
Pfaar O; Pieper-Fürst U; Mösges R
Immunotherapy; 2018 Jun; 10(7):525-528. PubMed ID: 29562789
[No Abstract] [Full Text] [Related]
5. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
[TBL] [Abstract][Full Text] [Related]
6. Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis.
Pfaar O; Lang S; Pieper-Fürst U; Astvatsatourov A; Gerich F; Klimek L; Kramer MF; Reydelet Y; Shah-Hosseini K; Mösges R
Allergy; 2018 Jan; 73(1):187-195. PubMed ID: 28675499
[TBL] [Abstract][Full Text] [Related]
7. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
8. Sublingual immunotherapy: allergen specific or placebo effect?
Kette F; Smith W
J Allergy Clin Immunol; 2011 Aug; 128(2):430; author reply 430-2. PubMed ID: 21665261
[No Abstract] [Full Text] [Related]
9. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis.
Ellis AK; Frankish CW; O'Hehir RE; Armstrong K; Steacy L; Larché M; Hafner RP
J Allergy Clin Immunol; 2017 Aug; 140(2):486-496. PubMed ID: 28236469
[TBL] [Abstract][Full Text] [Related]
10. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
11. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M
J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents.
Drachenberg KJ; Heinzkill M; Urban E; Woroniecki SR
Allergol Immunopathol (Madr); 2003; 31(5):270-7. PubMed ID: 14572416
[TBL] [Abstract][Full Text] [Related]
13. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
[TBL] [Abstract][Full Text] [Related]
14. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of injected allergen immunotherapy for treatment of grass pollen allergy in elderly patients with allergic rhinitis.
Bozek A; Cudak A; Walter Canonica G
Allergy Asthma Proc; 2020 Jul; 41(4):271-277. PubMed ID: 32605697
[No Abstract] [Full Text] [Related]
16. Effect of AIT in children including potential to prevent the development of asthma.
Valovirta E
Allergy; 2011 Jul; 66 Suppl 95():53-4. PubMed ID: 21668856
[TBL] [Abstract][Full Text] [Related]
17. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.
Nelson H; Lehmann L; Blaiss MS
Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864
[TBL] [Abstract][Full Text] [Related]
18. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients.
Howarth P; Malling HJ; Molimard M; Devillier P
Allergy; 2012 Mar; 67(3):321-7. PubMed ID: 22142377
[TBL] [Abstract][Full Text] [Related]
19. Grass pollen immunotherapy: where are we now.
Würtzen PA; Gupta S; Brand S; Andersen PS
Immunotherapy; 2016; 8(4):399-411. PubMed ID: 26973122
[TBL] [Abstract][Full Text] [Related]
20. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]